BENITEC BIOPHAR/S (NASDAQ:BNTC)’s stock price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $4.65 and traded as low as $3.20. BENITEC BIOPHAR/S shares last traded at $3.20, with a volume of 9,000 shares.
Separately, ValuEngine upgraded shares of BENITEC BIOPHAR/S from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd.
The company has a current ratio of 20.29, a quick ratio of 7.10 and a debt-to-equity ratio of 0.02. The business’s fifty day simple moving average is $4.63 and its 200-day simple moving average is $3.38.
An institutional investor recently bought a new position in BENITEC BIOPHAR/S stock. Sabby Management LLC bought a new position in shares of BENITEC BIOPHAR/S (NASDAQ:BNTC) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,365,615 shares of the biotechnology company’s stock, valued at approximately $971,000. BENITEC BIOPHAR/S comprises approximately 0.5% of Sabby Management LLC’s investment portfolio, making the stock its 11th biggest holding. Sabby Management LLC owned 106.69% of BENITEC BIOPHAR/S at the end of the most recent reporting period. 8.47% of the stock is currently owned by hedge funds and other institutional investors.
BENITEC BIOPHAR/S Company Profile (NASDAQ:BNTC)
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B.
Featured Story: Limitations of analyzing profit margin
Receive News & Ratings for BENITEC BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BENITEC BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.